ReviewThe world journal of men's health2022
The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review.
Review in The world journal of men's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Testicular ageing as a central hallmark of male senescence: characteristics, molecular mechanisms and emerging therapeutic strategies.Annals of medicine · 2026Review
- Targeting AMPK Networks for Male Reproductive Health: Mechanisms and Emerging Therapies.Cells · 2026Review
- The Impact of Diabetes Mellitus-Related Oxidative Stress on Male Fertility: A Review.Journal of diabetes · 2025Review
- Glycemic control and prostate antigen levels in individuals with diabetes based on NHANES data.Scientific reports · 2025Article
- Study Protocol: Evaluating the Impact of Diabetic Medications on Semen Quality: A Comparative Analysis of Diabetic Patients and Nondiabetic Controls with Correlation to Fertility Potential.Journal of pharmacy & bioallied sciences · 2025Article
- L-cysteine mitigates busulfan-induced testicular injury through modulation of CBS/HFrontiers in cell and developmental biology · 2025Article
- Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.European journal of clinical pharmacology · 2024Article
- Paternal metformin use and risk of congenital malformations in offspring in Norway and Taiwan: population based, cross national cohort study.BMJ (Clinical research ed.) · 2024Article
- Article
- Paternal Use of Metformin During the Sperm Development Period Preceding Conception and Risk for Major Congenital Malformations in Newborns.Annals of internal medicine · 2024Article
- Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature.International journal of molecular sciences · 2024 · on this mapReview
- The role of red ginseng in men's reproductive health: a literature review.Basic and clinical andrology · 2023Review
- Effect of Metformin on Lower Urinary Tract Symptoms in Male Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study in Taiwan.The world journal of men's health · 2023Article
- The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Diabetes as a potential compounding factor in COVID-19-mediated male subfertility.Cell & bioscience · 2022Review
- Metformin: Sex/Gender Differences in Its Uses and Effects-Narrative Review.Medicina (Kaunas, Lithuania) · 2022Review
- Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study.Frontiers in endocrinology · 2022Article
- Metformin's effects on varicocele, erectile dysfunction, infertility and prostate-related diseases: A retrospective cohort study.Frontiers in pharmacology · 2022Article
- The Effects of Separate and Combined Treatment of Male Rats with Type 2 Diabetes with Metformin and Orthosteric and Allosteric Agonists of Luteinizing Hormone Receptor on Steroidogenesis and Spermatogenesis.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin is the first-line oral antidiabetic drug that shows multiple pleiotropic effects of anti-inflamation, anti-cancer, anti-aging, anti-microbia, anti-atherosclerosis, and immune modulation. Metformin's effects on men's related health are reviewed here, focusing on reproductive health under subtitles of erectile dysfunction (ED), steroidogenesis and spermatogenesis; and on prostate-related health under subtitles of prostate specific antigen (PSA), prostatitis, benign prostate hyperplasia (BPH), and prostate cancer (PCa). Updated literature suggests a potential role of metformin on arteriogenic ED but controversial and contradictory effects (either protective or harmful) on testicular functions of testosterone synthesis and spermatogenesis. With regards to prostate-related health, metformin use may be associated with lower levels of PSA in humans, but its clinical implications require more research. Although there is a lack of research on metform's effect on prostatitis, it may have potential benefits through its anti-microbial and anti-inflammatory properties. Metformin may reduce the risk of BPH by inhibiting the insulin-like growth factor 1 pathway and some but not all studies suggest a protective role of metformin on the risk of PCa. Many clinical trials are being conducted to investigate the use of metformin as an adjuvant therapy for PCa but results currently available are not conclusive. While some trials suggest a benefit in reducing the metastasis and recurrence of PCa, others do not show any benefit. More research works are warranted to illuminate the potential usefulness of metformin in the promotion of men's health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.